Idera Pharmaceuticals

We are a biotechnology company engaged in the discovery and development of novel therapeutics that modulate immune responses through Toll-like receptors (TLR) for the treatment of multiple diseases.Idera Pharmaceuticals’ business strategy is to advance its clinical-stage cancer programs and to develop other applications of its technology through new partnerships. We currently are collaborating with Novartis to develop treatments for asthma and allergy indications

Contact Details: 345 Vassar Street Cambridge Massachusetts 02139 United States of America Tel: (617) 679-5500 Fax: (617) 679-5592 Email: info@iderapharma.com WWW: www.iderapharma.com/

Loading...

Recent Publications by Idera Pharmaceuticals:
Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies. We previously reported a novel class of stabilized immune-modulatory RNA...	15th October, 2009	Idera Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.	J Med Chem. 2009 Nov 12;52(21):6871-9. DOI Direct Link
Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8. Single-stranded RNAs act as ligands of Toll-like receptors (TLRs) 7 and 8...	6th August, 2009	Idera Pharmaceuticals, Inc., 167 Sidney Street, Cambridge, MA 02139, USA.	Biochem Biophys Res Commun. 2009 Aug 28;386(3):443-8. Epub 2009 Jun 11. DOI Direct Link
Modifications Incorporated in CpG Motifs of Oligodeoxynucleotides Lead to Antagonist Activity of Toll-like Receptors 7 and 9. Oligodeoxynucleotides (ODNs) containing unmethylated CpG dinucleotides act...	5th August, 2009	Idera Pharmaceuticals, Inc., 167 Sidney Street, Cambridge, Massachusetts	J Med Chem. 2009 Aug 3. DOI Direct Link
Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8. In continuation of our studies with stabilized immune modulatory RNA...	16th June, 2009	Idera Pharmaceuticals, Inc., 167 Sidney Street, Cambridge, MA 02139,	Bioorg Med Chem Lett. 2009 Apr 1;19(7):2044-7. Epub 2009 Feb 10. DOI Direct Link
Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9. Oligodeoxyribonucleotides containing unmethylated CpG motifs act as TLR9...	24th February, 2009	Idera Pharmaceuticals, Inc., 167 Sidney Street, Cambridge, Massachusetts	J Med Chem. 2009 Jan 22;52(2):551-8. DOI Direct Link
→View more Idera Pharmaceuticals research publications.

BioNews Results for Idera Pharmaceuticals:
Idera Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report	PR inside:  Nov 16 2009 9:58AM Matching: idera pharmaceuticals
Form 4 IDERA PHARMACEUTICALS, For: Nov 12 Filed by: MUELLER HANS	Street Insider:  Nov 12 2009 11:01PM Matching: idera pharmaceuticals
Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting	News-Medical.Net:  Nov 11 2009 5:54AM Matching: idera pharmaceuticals
Idera Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides Pipeline Update	Earthtimes.org:  Nov 5 2009 12:47PM Matching: idera pharmaceuticals
Idera Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides Pipeline Update	Freshnews.com:  Nov 5 2009 1:45PM Matching: idera pharmaceuticals
Promote your company here: BioNewsCast - Press Release Distribution	→View more Idera Pharmaceuticals news.

Idera Pharmaceuticals Clinical Trials:
Placebo-Controlled, Dose-Escalation Study of the Safety of IMO-2125 in Hepatitis C-Infected Patients

Idera Pharmaceuticals Patents:
US Patent No.	Title
7595305	Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
7105495	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
7115579	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
7173014	HIV-specific synthetic oligonucleotides and methods of their use
7176296	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
→View more Idera Pharmaceuticals patents.

Idera Pharmaceuticals (IDP) Financial information Links from Barchart
IDP Quote from from Barchart.com
IDP Chart from from Barchart.com
IDP Profile from from Barchart.com
IDP Opinion from from Barchart.com
→View more Idera Pharmaceuticals finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 464 times since April 2007, the link to the organisation's website has been followed 66 times

Recent Search Terms used to find this page: innate immune modulating drugs pipeline 2009 | Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8 | .

Search for more companies in Cambridge

Search for more companies in Massachusetts

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Idera Pharmaceuticals